Child Cancer Drug Trialled – Results Promising
Laboratory trials indicate that a new drug could be a valuable asset in combating three forms of cancer in children. The announcement, made at the National Cancer Research Institute Conference, was in respect of RH1 – described as possessing the ability to kill tumour cells related to Ewing’s sarcoma, osteosarcoma and neuroblastoma. The current generation of cancer treatments can prove ineffective on all three cancers.
The research involving RH1 took place at the University of Manchester, where the scientists involved observed how it promoted the death of cancerous cells by 50 per cent. While undertaken at pre-clinical level, the trials will, hope the scientists, lead to further assessment – this time, involving child patients.
RHI essentially stimulates cancer cells to self-destruct. While all cells have an inherent mechanism which causes such suicide to take place when damage or uncontrollable growth occurs, those with cancer cause the procedure to either malfunction or cease functioning entirely.
The first tranche of RH1’s trial involved the participation of adult patients with cancer. In this, it was found to operate particularly effectively in respect of tumours containing the DT-diaphorase enzyme – typically found in breast, lung and liver cancers.
According to Dr Guy Makin, the head researcher involved in RH1’s assessment, to be associated with a child cancer drug that had only just finished being trialled in adults was “very exciting”. He added: "We hope that this will be just the first of many new agents that we can show are useful for treating childhood cancer,"
As per data issued by Cancerbacup, 100 new instances of neuroblastoma and 60 new cases of either Ewing’s sarcoma or osteosarcoma are observed in children in the UK per year.
"Survival rates for children with cancer are high at 75%," stated the Children's Cancer and Leukaemia Group’s Chairman, Dr Bruce Morland.
"But in many cases, patients become resistant to their drugs and need new options."
Source – Pharmaceutical International’s Health Reporter
Recent related News Items:
NICE to Reconsider Approving Lung Cancer Drug
Alzheimer's Drugs Proposed for Breast Cancer Patients
US FDA Issues Safety Warning on Cancer Drug Fentora
Further Resources:
